Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Precision BioSciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
DTIL
Nasdaq
8731
https://precisionbiosciences.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Precision BioSciences Inc
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
- Apr 17th, 2024 11:36 am
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
- Apr 16th, 2024 8:15 pm
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
- Apr 11th, 2024 1:55 pm
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
- Apr 2nd, 2024 1:55 pm
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
- Apr 2nd, 2024 10:48 am
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
- Mar 27th, 2024 12:10 pm
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
- Mar 27th, 2024 10:45 am
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
- Mar 20th, 2024 8:30 pm
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
- Mar 19th, 2024 11:00 am
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
- Mar 6th, 2024 1:45 pm
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
- Mar 1st, 2024 11:30 am
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
- Feb 29th, 2024 9:01 pm
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
- Feb 27th, 2024 9:25 am
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
- Feb 20th, 2024 12:00 pm
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
- Feb 14th, 2024 12:00 pm
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
- Feb 13th, 2024 12:00 pm
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
- Feb 12th, 2024 12:00 pm
Precision BioSciences to Effect a Reverse Stock Split
- Feb 9th, 2024 12:00 pm
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
- Jan 9th, 2024 12:00 pm
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
- Jan 9th, 2024 12:00 pm
Scroll